Abstract PS4-06-28: Initial clinical and pharmacology results from START-002: A phase 1b/2 clinical investigation of invikafusp alfa (STAR0602), a first-in-class dual T cell agonist, in combination with sacituzumab govitecan in patients with mTNBC or HR+/HER2- mBC
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Institutions: Massachusetts General Hospital, University of Southern California, USC Norris Comprehensive Cancer Center, Princess Margaret Cancer Centre, University of California, Los Angeles, UCLA Health, UCLA Jonsson Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The University of Texas at San Antonio Health Science Center, Sarah Cannon
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129367339